Mirae Company Supplies Laparoscopic Surgery Robot 'Revo-i' to Domestic Public Medical Institutions for the First Time

[Asia Economy Reporter Jang Hyowon] Mirae Company announced on the 1st that it will supply the laparoscopic surgical robot ‘Revo-i’ (hereinafter, Revo-i) to the Korea Institute of Radiological & Medical Sciences Nuclear Hospital (hereinafter, Nuclear Hospital). As Revo-i is supplied for the first time to a general hospital-level public medical institution, surgical references for a wider range of indications are expected to increase rapidly.

The Nuclear Hospital, established in 1963, is the first cancer-specialized hospital in Korea under the Korea Institute of Radiological & Medical Sciences, Ministry of Science and ICT. In 2021, it was selected for the third consecutive year in the tumor category of the world’s best hospitals ‘World Best Hospital 2021’ by the global news weekly Newsweek in the United States, playing a pivotal role in improving national health and welfare. In particular, it has been proven to be the top cancer-specialized hospital in Korea by receiving the highest grade for seven consecutive years in breast cancer and five consecutive years in stomach cancer in the adequacy evaluation conducted by the Health Insurance Review & Assessment Service, which assesses the level of cancer treatment.

The Nuclear Hospital has already completed the establishment of advanced infrastructure facilities for robotic surgery, including operating rooms dedicated to surgical robots, and has secured excellent medical staff skilled in robotic surgery techniques in various fields such as urology, otolaryngology, thoracic surgery, and obstetrics and gynecology. In particular, Dr. Song Kanghyun of the Department of Urology and Dr. Lee Myungcheol of the Department of Otolaryngology have completed robotic surgery training held at Stanford University School of Medicine in the United States and have also participated in the joint surgical robot research and development process, thus possessing abundant experience and expertise in surgical robot techniques.

Through the introduction of the laparoscopic surgical robot Revo-i at the Nuclear Hospital, which possesses world-class cancer treatment experts and infrastructure, Mirae Company plans to accumulate clinical data on various indications to further promote the excellence of Revo-i. In addition, it intends to pursue qualitative growth in the surgical robot business through product advancement based on feedback from medical staff.

Revo-i, the first laparoscopic surgical robot developed domestically, was designated as the ‘10th Innovative Medical Device’ by the Ministry of Food and Drug Safety in May, recognizing its advanced technology in the field of medical robot technology. Furthermore, by successfully conducting additional clinical studies in high-difficulty cancer surgery areas such as urology, hepatobiliary-pancreatic surgery, and colorectal surgery at Severance Hospital, Revo-i has secured clinical safety and reliability.

Kim Jungoo, CEO of Mirae Company, said, “Introducing Revo-i to the Nuclear Hospital is very encouraging for our surgical robot business,” adding, “We will make every effort to provide full support from training to maintenance so that better medical services can be provided to more patients through Revo-i robotic surgery at the Nuclear Hospital.”

He also stated, “By reflecting clinical data and feedback from robotic surgeries for cancer and other diseases at the Nuclear Hospital to further advance surgical instruments and leading the derivation of appropriate fees for robotic surgery use, we will strive to make the product trusted by more medical professionals and patients.”